Bernd Dörken

Q: What Schools Are Affiliated With Bernd Dörken

Bernd Dörken is affiliated with the following schools: Humboldt University of Berlin, Hannover Medical School, University of Washington

Bernd Dörken's AcademicInfluence.com Rankings

Bernd Dörken

Philosophy

#6232

World Rank

#9234

Historical Rank

Logic

#3415

World Rank

#4568

Historical Rank

philosophy Degrees

Bernd Dörken

Biology

#8423

World Rank

#11495

Historical Rank

Developmental Biology

#104

World Rank

#110

Historical Rank

Immunology

#483

World Rank

#500

Historical Rank

Molecular Biology

#1066

World Rank

#1090

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Bernd Dörken's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Bernd Dörken Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bernd Dörken's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oncogene-induced senescence as an initial barrier in lymphoma development (2005) (1182)
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. (1997) (832)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. (2010) (779)
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. (2003) (776)
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. (1996) (650)
Senescence-associated reprogramming promotes cancer stemness (2017) (564)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (2012) (507)
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression (1997) (441)
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. (2009) (439)
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy (2013) (429)
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. (2002) (405)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. (2000) (387)
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. (2010) (374)
Aberrantly expressed c‐Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF‐κB (2002) (367)
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. (2014) (367)
High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. (1996) (345)
Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. (1986) (325)
Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells (1999) (321)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. (2011) (318)
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma (2010) (310)
Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma (2013) (298)
Nuclear Factor κB–dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity (2002) (286)
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. (1999) (284)
Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. (2001) (266)
Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. (2001) (259)
Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) (2005) (254)
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma (2013) (240)
Antisense therapy in oncology: new hope for an old idea? (2001) (228)
Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. (2003) (219)
c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis (2004) (217)
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. (2004) (212)
Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines (2011) (209)
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. (2015) (209)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib (2013) (209)
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. (2012) (207)
Pathogenesis of non-Hodgkin's lymphoma. (2011) (201)
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. (1996) (198)
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma (2006) (196)
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. (2002) (195)
Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells (2002) (193)
APO‐1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl‐2 oncogene expression (1993) (192)
Towards a better definition of human leucocyte surface molecules. (1989) (191)
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. (1999) (185)
Identification of Apoptosis-associated Proteins in a Human Burkitt Lymphoma Cell Line (1998) (184)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. (2017) (181)
Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop (2003) (177)
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. (2000) (171)
Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo (2000) (170)
Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts (2001) (164)
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. (1987) (162)
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. (1998) (161)
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. (2006) (160)
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 (2004) (159)
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. (1986) (158)
Apoptosis-induced Cleavage of β-Catenin by Caspase-3 Results in Proteolytic Fragments with Reduced Transactivation Potential* (2000) (158)
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. (2010) (157)
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. (1999) (155)
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy (2003) (155)
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. (2000) (153)
Apoptosis: implications of basic research for clinical oncology. (2001) (153)
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. (2003) (152)
Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells (2003) (151)
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study (2008) (148)
Severe peripheral arterial disease during nilotinib therapy. (2011) (148)
Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis (2003) (148)
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). (2004) (147)
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation (2009) (143)
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. (2005) (142)
Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. (1987) (141)
Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells (2010) (140)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct (2003) (131)
Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. (1990) (131)
Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution (2007) (131)
Brain metastases in breast cancer: prognostic factors and management. (1999) (129)
Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. (1997) (129)
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. (2004) (128)
PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells (2004) (126)
Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms (2005) (126)
Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. (2001) (125)
The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. (1988) (124)
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. (1997) (121)
Cellular senescence in cancer treatment: friend or foe? (2004) (121)
Induction of cell death by the BH3‐only Bcl‐2 homolog Nbk/Bik is mediated by an entirely Bax‐dependent mitochondrial pathway (2003) (120)
Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance (2001) (120)
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis (2018) (120)
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study (2014) (119)
Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis (2002) (118)
Induction of the death‐promoting gene bax‐α sensitizes cultured breast‐cancer cells to drug‐induced apoptosis (1996) (116)
Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets (1988) (114)
5‐Aza‐2′‐deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53‐independent apoptosis in myeloid leukemia (2005) (113)
Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas (2005) (111)
Chemotherapy in alveolar soft part sarcomas. What do we know? (2003) (111)
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. (2005) (109)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (2003) (108)
Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. (2002) (105)
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma (2006) (104)
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma (2009) (103)
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. (2011) (102)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. (2002) (102)
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. (2011) (102)
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes (2015) (100)
Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. (1988) (100)
Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) (2005) (100)
Costimulation by CD137/4–1BB inhibits T cell apoptosis and induces Bcl‐xL and c‐FLIPshort via phosphatidylinositol 3‐kinase and AKT/protein kinase B (2005) (98)
Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. (1997) (98)
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. (1998) (96)
Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, Bp 130/140. (1987) (95)
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. (2008) (95)
Clinical cardiac safety profile of nilotinib (2012) (95)
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma (2013) (94)
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. (2000) (94)
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. (2018) (92)
The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. (2007) (92)
Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccines (1995) (91)
CD Antigens 1989 (1989) (91)
Stroma-Mediated Dysregulation of Myelopoiesis in Mice Lacking IκBα (2005) (91)
C/EBPbetaDeltauORF mice--a genetic model for uORF-mediated translational control in mammals. (2010) (91)
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity (2001) (90)
Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. (2006) (90)
Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. (1997) (89)
Cellular senescence predicts treatment outcome in metastasised colorectal cancer (2010) (88)
Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway (2004) (87)
Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation (2002) (87)
Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors (2001) (87)
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics (1999) (86)
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy) (2008) (85)
Induction of HLA class‐II antigen expression on human carcinoma cell lines by IFN‐gamma (1985) (84)
A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. (2010) (84)
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. (2005) (84)
The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. (1995) (83)
Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. (1989) (83)
Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed–Sternberg cells (2012) (82)
Differential Eµ enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B‐cell populations, B‐cell non‐Hodgkin lymphomas, and Hodgkin lymphomas (2004) (82)
Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. (1997) (82)
Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. (1988) (79)
Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway (2005) (78)
Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab (2007) (77)
Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cells (2004) (77)
Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved (2003) (77)
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. (2015) (75)
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. (1993) (73)
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. (2016) (73)
GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. (2000) (72)
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells (2010) (71)
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 (2000) (71)
Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma (2008) (71)
Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells (2006) (70)
Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma (2010) (70)
Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors (2002) (69)
Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. (2005) (68)
C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. (2009) (68)
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia (2002) (68)
In vivo expression of survivin and its splice variant survivin‐2B: Impact on clinical outcome in acute myeloid leukemia (2006) (67)
The IL‐6 receptor antagonist SANT‐7 overcomes bone marrow stromal cell–mediated drug resistance of multiple myeloma cells (2001) (67)
TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway (2005) (67)
The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines (2002) (67)
Imatinib‐induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia (2002) (66)
Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. (2005) (66)
Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. (2011) (65)
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. (2010) (64)
A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia (2010) (64)
Activated Notch 1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma (2002) (63)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (2005) (63)
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features (2016) (62)
Notch signaling in leukemias and lymphomas. (2008) (62)
IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. (2013) (61)
Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. (2014) (61)
Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. (2014) (60)
The Golgi Protein RCAS1 Controls Cell Surface Expression of Tumor-associated O-Linked Glycan Antigens* (2003) (60)
Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene (2000) (60)
HLA B27 and defects in the T‐cell system in Whipple's disease (1979) (60)
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice (1993) (60)
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. (1998) (60)
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. (2005) (59)
Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. (1997) (59)
Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis (2003) (58)
Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. (1999) (57)
Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation (2001) (57)
Inhibition of CPP32 blocks surface IgM‐mediated apoptosis and D4‐GDI cleavage in human BL60 Burkitt lymphoma cells (1998) (57)
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia (2017) (56)
Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation (1998) (56)
Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. (2014) (55)
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. (2007) (54)
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma (2018) (54)
Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability (2003) (54)
Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias (2005) (53)
Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: evidence for hematopoietic plasticity (2010) (53)
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: A phase II-study and historical comparison with the surgical approach (2007) (53)
Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells (1997) (51)
The sorting receptor Sortilin exhibits a dual function in exocytic trafficking of interferon-γ and granzyme A in T cells. (2012) (50)
Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report (2006) (50)
Anatomical variations in the internal jugular veins of cancer patients affecting central venous access. Anatomical variation of the internal jugular vein. (2001) (49)
Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. (1999) (49)
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis (2007) (49)
Constitutive expression levels of CD95 and Bcl‐2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia (2000) (49)
Induction of apoptosis by enediyne antibiotic calicheamicin ϑII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner (2003) (48)
Induction of Bax‐α precedes apoptosis in a human B lymphoma cell line: potential role of the bcl‐2 gene family in surface IgM‐mediated apoptosi (1995) (48)
Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells (2006) (48)
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway (2004) (48)
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia (2010) (47)
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. (2013) (47)
p14ARF Induces G2 Cell Cycle Arrest in p53- and p21-deficient Cells by Down-regulating p34cdc2 Kinase Activity* (2005) (47)
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma (2014) (47)
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma (2013) (47)
A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation (2008) (46)
Epstein–Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course (2006) (46)
High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas (2010) (46)
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. (2002) (46)
Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation (2013) (45)
Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. (1999) (45)
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment (2003) (45)
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. (2014) (44)
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma (2011) (44)
Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. (1996) (43)
SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. (2017) (42)
B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. (1988) (42)
Blood group determinates incidence for pancreatic cancer in Germany (2013) (42)
Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. (2008) (42)
Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. (1993) (42)
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. (2007) (42)
Does long‐term survival in patients with pancreatic cancer really exist?—Results from the CONKO‐001 study (2013) (41)
Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice (1996) (41)
Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis (2002) (41)
Two types of TNF receptors are expressed on human normal and malignant B lymphocytes. (1991) (40)
Direct and indirect T cell priming by dendritic cell vaccines (1999) (40)
Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model (2014) (39)
Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. (1987) (39)
EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin. (2005) (39)
T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogeneous IL-2. (1989) (38)
Vaccination with autologous non‐irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia (2007) (38)
Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway (2005) (38)
Autologous peripheral blood stem cell transplantation: analysis of autografted cells and lymphocyte recovery. (1989) (37)
Activation and activation‐induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO‐1) ligand expression and function (1997) (37)
HD37 Monoclonal Antibody: A Useful Reagent for Further Characterization of “Non-T, Non-B” Lymphoid Malignancies (1986) (37)
Multiple myeloma cells modify VEGF/IL‐6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR‐223 (2016) (36)
Tumor Stroma-Derived TGF-b Limits Myc-Driven Lymphomagenesis via Suv 39 h 1-Dependent Senescence (2009) (36)
Bax expression in benign and malignant thyroid tumours: Dysregulation of wild‐type P53 is associated with a high Bax and P21 expression in thyroid carcinoma (2001) (35)
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. (2014) (35)
NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. (2013) (34)
Empirical antimicrobial monotherapy in patients after high‐dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial (2005) (34)
Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. (1986) (34)
NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia (2012) (34)
Loss of p21 disrupts p14ARF-induced G1 cell cycle arrest but augments p14ARF-induced apoptosis in human carcinoma cells (2005) (33)
Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells. (1990) (33)
A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants (2011) (33)
Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study (2009) (33)
Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis (2005) (32)
CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity (2007) (32)
HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model (2012) (32)
Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity (2004) (32)
Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties (2003) (31)
G protein subunit G alpha 16 expression is restricted to progenitor B cells during human B-cell differentiation. (1995) (31)
Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy (2008) (31)
Mitoxantrone and high‐dose cytarabine as salvage therapy for refractory non‐Hodgkin's lymphoma (1989) (31)
CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study. (2015) (30)
Extravasations of oxaliplatin. (2003) (30)
Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy (2013) (30)
Immunophenotypic similarities of mediastinal clear‐cell lymphoma and sinusoidal (monocytoid) b cells (1989) (30)
Expression of HLA‐A, B, C, β2‐microglobulin (β2m), HLA‐DR, ‐DP, ‐DQ and of HLA‐D‐associated invariant chain (Ii) in soft‐tissue tumors (1990) (29)
Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome (2015) (29)
Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia (2000) (29)
The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome (2012) (29)
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model (2011) (28)
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. (2012) (28)
Nuclear Factor B – dependent Gene Expression Profiling of Hodgkin ’ s Disease Tumor Cells , Pathogenetic Significance , and Link to Constitutive Signal Transducer and Activator of Transcription 5 a Activity (2002) (28)
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis (2005) (27)
A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). (2006) (27)
Filgrastim‐induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging (2004) (27)
Transcriptional regulation of human survivin by early growth response (Egr)‐1 transcription factor (2008) (27)
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma (2018) (27)
CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion. (1991) (26)
Reduced-Intensity Conditioning Using Fludarabine and Antithymocyte Globulin Alone Allows Stable Engraftment in a Patient with Dyskeratosis Congenita (2010) (26)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis (2019) (26)
Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB (2004) (25)
BAY 43‐9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines (2011) (25)
CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC (2012) (25)
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy (2006) (25)
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker (2005) (25)
Peripheral blood sCD3− CD4+ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma (2014) (25)
A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003 (2007) (25)
Cooperative effect of p21Cip1/WAF−1 and 14-3-3σ on cell cycle arrest and apoptosis induction by p14ARF (2008) (24)
Intraoperative fresh-frozen plasma versus human albumin in craniofacial surgery − A pilot study comparing coagulation profiles in infants younger than 12 months (2007) (24)
Involvement of NAK‐1, the human nur77 homologue, in surface IgM‐mediated apoptosis in Burkitt lymphoma cell line BL41 (1995) (24)
Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?—Results From the CONKO Study Group (2016) (24)
Jagged 1-induced Notch signaling drives proliferation of multiple myeloma cells (2004) (23)
Oral Trofosfamide: An Active and Well-Tolerated Maintenance Therapy for Adult Patients with Advanced Bone and Soft Tissue Sarcomas. Results of a Retrospective Analysis (2002) (23)
CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma (2016) (23)
Induction of features characteristic of hairy cell leukemia in chronic lymphocytic leukemia and prolymphocytic leukemia cells. (1986) (23)
The molecular biology of diffuse large B-cell lymphoma (2011) (23)
p14ARF-induced Apoptosis in p53 Protein-deficient Cells Is Mediated by BH3-only Protein-independent Derepression of Bak Protein through Down-regulation of Mcl-1 and Bcl-xL Proteins (2012) (23)
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia (2015) (23)
CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. (1999) (22)
Lack of correlation between rejection of tumor cells co‐expressing interleukin‐2 and B7.1 and vaccine efficiency (1997) (22)
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study (2011) (22)
The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells (2014) (22)
Aberrant expression of the Th 2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT 3 signaling and attracts Treg cells via regulation of MIP-3 (2008) (22)
Monoclonal antibodies against the human lymphocyte differentiation antigen CD 76 bind to gangliosides (1990) (21)
C/EBP b D uORF mice—a genetic model for uORF-mediated translational control in mammals (2009) (21)
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. (2016) (21)
Human Lyb‐2 homolog CD72 is a marker for progenitor B‐cell leukemias (1992) (20)
Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer (2013) (20)
CCL19 (ELC) improves TH1‐polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model (2012) (20)
Characterization of a Human B Lymphocyte-Specific Antigen Defined by Monoclonal Antibodies HD6 and HD39 (1986) (20)
Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study. (1999) (19)
Identification of a chemokine receptor profile characteristic for mediastinal large B‐cell lymphoma (2009) (19)
Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial. (2009) (19)
Silencing of APAF‐1 in B‐CLL results in poor prognosis in the case of concomitant p53 mutation (2006) (19)
Characterization of apoptosis-induced Mcm3 and Cdc6 cleavage reveals a proapoptotic effect for one Mcm3 fragment (2004) (19)
The tumor-associated antigen EBAG9 negatively regulates the cytolytic capacity of mouse CD8+ T cells. (2009) (19)
A comparison of membrane marker phenotypes in hairy-cell leukemia and phorbol-ester induced B-cll cells using monoclonal antibodies. (1985) (19)
Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis (2006) (19)
Nilotinib for the treatment of chronic myeloid leukemia (2008) (19)
Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil plus Folinic Acid in Combination with Mitomycin C for the Treatment of Advanced Gastric Cancer (2000) (18)
Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation (2016) (18)
Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogeneous IL-2. (1989) (18)
Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo (2002) (18)
LBA18CONKO-006: A RANDOMIZED DOUBLE-BLINDED PHASE IIB-STUDY OF ADJUVANT THERAPY WITH GEMCITABINE + SORAFENIB/PLACEBO FOR PATIENTS WITH R1-RESECTION OF PANCREATIC CANCER (2014) (18)
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial (2014) (18)
Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. (1987) (18)
Reprogramming of B Lymphoid Cells in Human Lymphoma Pathogenesis (2006) (18)
Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. (2015) (18)
Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study (2001) (17)
Allogeneic vaccination for renal cell carcinoma: development and monitoring (2000) (17)
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma (2012) (17)
Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. (2004) (16)
Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization (2004) (16)
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. (2006) (16)
Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. (1998) (16)
AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival (2018) (16)
Role of crown-like side chains in the biological activity of substituted-phenoxazone drugs. (2000) (16)
Clinical relevance of blast cell phenotype as determined with monoclonal antibodies in acute lymphoblastic leukemia of adults. (1987) (15)
Ligand-dependent modulation of membrane phospholipid metabolism in ConA-stimulated lymphocytes. (1978) (15)
Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation. (1998) (15)
Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation (2001) (15)
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: A phase II-study (NCT00356161) (2013) (15)
Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study (2003) (15)
BCR‐ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients (2010) (15)
Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype (2010) (14)
Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis (2007) (14)
CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model (2016) (14)
Dendritic cell-mediated survival signals in Eμ-Myc B-cell lymphoma depend on the transcription factor C/EBPβ (2014) (14)
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. (2018) (14)
Prognostic Value of Multimarker Analysis in Stage III Colorectal Cancer: One Step Forward Towards an Individualized Therapy Decision (2005) (14)
BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease? (2018) (14)
Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo (2005) (14)
A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomy. (1987) (13)
Overexpression of the death‐promoting gene bax‐α sensitizes human BL‐41 Burkitt lymphoma cells for surface IgM‐mediated apoptosis (1997) (13)
Polymerase chain reaction monitoring shows a high efficacy of clinical immunomagnetic purging in patients with centroblastic-centrocytic non-Hodgkin's lymphoma. (1992) (13)
Erratum: Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma (Cancer Cell (2018) 33(2) (322–336.e8) (S1535610818300023) (10.1016/j.ccell.2018.01.002)) (2018) (13)
Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient (2004) (13)
5′-AZA-2′-Deoxycytidine Induces p21/WAF Expression by Demethylation of p73 Leading to p53-Independent Apoptosis in Myeloid Leukemia. (2004) (13)
Identity of HML‐1 Antigen on Intestinal Intraepithelial T Cells and of B‐ly7 Antigen on Hairy Cell Leukaemia (1990) (13)
Hepatic Arterial Infusion with Oxaliplatin and 5-FU/Folinic Acid for Advanced Biliary Tract Cancer: A Phase II Study (2013) (13)
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy—results of a randomized trial (2003) (13)
Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients. (2004) (12)
Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia (2015) (12)
Discordant differentiation antigen pattern in a case of Richter's syndrome with monoclonal idiotype expression and immunoglobulin gene rearrangement. (1990) (12)
BCR-ABL1+ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1- Subclone as a Cause of Refractory Disease with Nilotinib Treatment (2014) (12)
TPA-Induced Modulation of B Cell Differentiation Antigens Defined by Monoclonal Antibodies (HD6, HD28, HD37, HD39) (1986) (11)
T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia (2004) (11)
A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells In Vivo (2017) (11)
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone (2012) (11)
Decreased generation of anti‐tumor immunity after intrasplenic immunization (2001) (11)
High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS (2014) (11)
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma (2016) (11)
Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. (2005) (11)
Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. (2004) (11)
Comparison of multiple rosetting assays for detecting antibody reactivity of different immunoglobulin classes against surface antigens of benign and malignant tissue culture cells. (1980) (11)
Increased heterogeneity of serum thyroglobulin in thyroid cancer patients as determined by monoclonal antibodies (1986) (10)
Purine degradative enzymes and immunological phenotypes in chronic B‐lymphocytic leukaemia: indications that leukaemic immunocytoma is a separate entity (1986) (10)
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. (1997) (10)
Impairment of Circulating Myeloid Dendritic Cells in Immunosuppressed Renal/Pancreas Transplant Recipients (2006) (10)
Enhanced myelopoiesis in long-term cultures of human bone marrow pretreated with recombinant granulocyte-macrophage colony-stimulating factor. (1989) (10)
Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. (1990) (10)
Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. (2001) (10)
Cetuximab: appraisal of a novel drug against colorectal cancer. (2007) (10)
Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia‐reactive T cells in patients with chronic myeloid leukaemia (2006) (9)
Need for safety goggles for endoscopy. (2003) (9)
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma. (2017) (9)
Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML (2003) (9)
[Accuracy of the sonographic determination of the splenic weight in comparison with the weight at autopsy]. (2003) (9)
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene‐modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor‐induced immunosuppression and a possible role for NF‐κB (2015) (9)
Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation (2017) (9)
Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines (2014) (9)
A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells (2004) (9)
Screening for expression of cytokines with hematopoietic growth factor activity by permanent human B-cell lines. (1991) (9)
Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3 (2010) (8)
An immunoenzymatic staining assay (ISA) for the rapid screening of monoclonal antibodies detecting membrane and cytoplasmic antigens. (1986) (8)
Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial. (2014) (8)
Cardiac damage in autologous bone marrow transplant patients: An autopsy study (1988) (8)
Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission (2014) (8)
Autologous transplantation of a bone marrow graft manipulated by chemoseparation to eliminate residual tumor cells (1983) (8)
Immunomodulatory molecules in renal cell cancer: CD80 and CD86 are expressed on tumor cells (2017) (8)
Downregulation of genes involved in DNA repair and differential expression of transcription regulators and phosphatases precede IgM-induced apoptosis in the Burkitt's lymphoma cell line BL60-2. (2004) (8)
Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes (2002) (7)
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group (2011) (7)
Lymphotoxin‐α/β heterodimer is expressed on leukemic hairy cells and activated human B lymphocytes (1994) (7)
Acute hypokalemic tetraparesis induced by intravenous methotrexate. (2003) (7)
Loss of p21 disrupts p14ARF-induced G1 cell cycle arrest but augments p14ARF induced apoptosis in human carcinoma cells (2005) (7)
[Therapy of Zenker's diverticulum]. (2002) (7)
Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study (2005) (7)
Panhypopituitarism in a Patient with Breast Cancer (2004) (7)
Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia (2015) (6)
Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate‐risk karyotype in first complete remission (2015) (6)
CD Antigens 1989: Summary of Nomenclature System for Human Leacocyte Surface Antigens. (1989) (6)
[Antimicrobial therapy in neutropenia]. (2008) (6)
Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8 (2000) (6)
Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene. (2004) (6)
CD52 Is Not a Promising Immunotherapy Target for Most Patients with Multiple Myeloma (2005) (6)
Morphologic diagnosis of leukaemic B-lymphoproliferative disorders and the role of cyclin D1 expression (2002) (6)
Fatal immune haemolysis due to antibodies to individual metabolites of 5‐fluorouracil (2010) (5)
Severe Thrombocytopenia in a Patient with Metastatic Renal Cell Carcinoma (2009) (5)
Dendritic Cells Vaccination in BCR/ABL-Positive Chronic Myeloid Leukemia - Final Results of a Phase I/II Study. (2004) (5)
Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): Final analysis of a clinical phase I/II study. (2012) (5)
Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. (2012) (5)
Allogeneic Stem Cell Transplantation For Cytogenetically Normal Acute Myeloid Leukemia: Impact Of FLT3 and NPM1 Mutational Status (2013) (5)
Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines. (1988) (5)
Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma; a randomized phase II study (2001) (5)
Frequent induction of chromosomal aberrations in in vivo skin fibroblasts after allogeneic stem cell transplantation: hints to chromosomal instability after irradiation (2015) (5)
Anti-leukemia T cells in AML (2013) (4)
Clinical Lessons to Be Learned from Patients Developing Chronic Myeloid Leukemia While on Immunosuppressive Therapy after Solid Organ Transplantation: Yet Another Case after Orthotopic Heart Transplantation (2014) (4)
Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma (2013) (4)
Phenotypic modulation of chronic lymphocytic, prolymphocytic, and lymphoplasmacytic leukemia cells by TPA: induction of TRAP isoenzyme 5 and HD6 (CD22) antigen and enhancement of IgM messenger RNA. (1987) (4)
Monoclonal antibody uptake in B-cell lymphomas: Experimental studies in nude mouse xenografts (2005) (4)
[Project graph technique for time management in abdominal ultrasound evaluations]. (1999) (4)
Analysis of Ten B Lymphocyte-Specific Workshop Monoclonal Antibodies (1986) (4)
The effect of human recombinant GM-CSF on the myelopoiesis in a long-term bone marrow culture (LTBMC). (1988) (4)
Granulocyte Macrophage-Colony Stimulating Factor Plus Interleukin-2 Plus α-interferon Plus 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer: Induction of CD80/86+ T Cells Indicates Adverse Outcome (2009) (4)
Immunological Classification of “Unclassifiable” Acute Leukemia (1986) (4)
Eukaryotic initiation factor 2α phosphorylation is required for B-cell maturation and function in mice (2011) (4)
Allogeneic stem cell transplantation (allo SCT) in adult ALL: Does prophylactic donor lymphocyte infusion (DLI) improve survival? (2005) (4)
JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia (2014) (4)
Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time (2008) (4)
Successful autologous transplantation of immunomagnetic bead purged bone marrow in non-Hodgkin's lymphoma. (1992) (4)
Necrotic death but not irradiation abolishes costimulation of T‐cell effector functions and survival by CD80‐expressing tumor cells (2005) (4)
SPARC in pancreatic cancer: Results from the CONKO-001 study. (2013) (4)
Long-term disease-free survival following autologous bone marrow/blood stem cell transplantation in 89 patients with acute leukemia. (1990) (4)
Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in Western patients. (2011) (4)
Post-transplantation chronic myeloid leukemia. (2011) (4)
Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts (2008) (3)
IκBα is required for marginal zone B cell lineage development (2008) (3)
A comparative analysis of human bone marrow-resident and peripheral memory B cells. (2018) (3)
Decitabine: Where Is the Target?. (2005) (3)
Constitutive NFk B maintains high expression of a characteristic gene network , including CD 40 , CD 86 , and a set of antiapoptotic genes in Hodgkin / Reed-Sternberg cells (2001) (3)
Differential expression of SHP-1 in chronic myeloid leukemia (2015) (3)
Intrapericardial Application of Mitoxantrone for Treatment of Malignant Pericardial Effusion (1994) (3)
Eight Cycles of Escalated-Dose BEACOPP Compared With FourCycles of Escalated-Dose BEACOPP Followed by Four Cycles ofBaseline-Dose BEACOPP With or Without Radiotherapy in PatientsWith Advanced-Stage Hodgkin’s (2011) (3)
[Docetaxel in treatment of other solid tumors]. (1997) (3)
Weekly combination of oxaliplatin (OX) and irinotecan (IRI) in 5-FU resistant colorectal cancer (CRC) (2001) (3)
Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease☆ (2013) (3)
Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection (2006) (3)
SEQUENTIAL TREATMENT WITH RITUXIMAB AND CHOP CHEMOTHERAPY IN B-CELL PTLD – WILL RISK STRATIFIED SEQUENTIAL TREATMENT BECOME THE NEW STANDARD IN THERAPY?: 292 (2008) (3)
The Value of Weekly High Dose Infusional 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer (1997) (3)
EBP regulates transcription factors critical for proliferation and survival of multiple myeloma cells (2009) (3)
Capecitabine and docetaxel for advanced gastric cancer. (2006) (3)
The use of microarray technologies in mantle cell lymphoma. (2011) (3)
CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial. (2010) (3)
[The role of polychemotherapy in the management of malignant bone tumors]. (2002) (3)
6513 Successful prevention of symptomatic thromboembolic events by the low molecular weight heparin enoxaparin in patients with advanced pancreatic cancer – results of the CONKO 004 trial (2009) (3)
Clonal Hematopoiesis: Cell of Origin, Lineage Repartition and Dynamic Evolution during Chemotherapy (2017) (3)
Analysis of the B Cell/Leukemia Workshop Monoclonal Antibodies Using an Immunoenzymatic Staining Assay and a Radioimmunoassay on Cells (1986) (3)
Recurrent Gastric Adenocarcinoma with Unusual Metastatic Localization and Excellent Responseto Docetaxel and 5-FU Continuous Infusion (2003) (3)
Experimental Approaches to Tumor Therapy with Monoclonal Antibodies (1989) (2)
Anti-CD20 Immunotherapy Augments the Chemotherapy-Induced Senescence Response In Human Lymphoma Cells (2010) (2)
Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation. (2015) (2)
Quantitation of μ mRNA byin situ hybridization reveals a correlation between B-maturation associated antigens and IgM gene activation in acute lymphatic leukemias (1988) (2)
Detection of small numbers of cells characteristic for haematological disorders in peripheral blood (the deep diff). (2002) (2)
Increased MSI2 expression Is Associated with Aggressive CML and AML (2011) (2)
Natural History, Risk Factors and Prognostic Impact of Graft-Versus-Host Disease Classified According to the National Institute of Health Criteria in Patients Receiving Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (2010) (2)
Survivin Is Negatively Regulated by Early Growth Response (Egr)-1 Transcription Factor in Acute Myeloid Leukemia. (2006) (2)
Monoclonal Antibody (HD 39) Reactive with a Human B Lymphocyte Specific Antigen Expressed on Late Stages of B Cell Maturation (1985) (2)
Coexpression of p21WAF1/CIP1 in adenovirus vector transfected human primary hepatocytes prevents apoptosis resulting in improved transgene expression (2003) (2)
Safety and efficacy of stem cell mobilization under imatinib therapy. (2003) (2)
Gemcitabine: results from the CONKO-001 study (2014) (2)
Non-Genotoxic Targeting of p53-Dependent and p53-Independent Signaling Pathways Efficiently Kills Hodgkin/Reed-Sternberg Cells. (2005) (2)
Monoclonal anti-idiotype antibodies against lymphoma-associated cold agglutinins (1983) (2)
C/EBPb mice—a genetic model for uORF-mediated translational control in mammals (2009) (2)
TNFα therapy activates human B-lymphoma cells in vivo and may protect myelopoiesis☆ (1992) (2)
Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy (2008) (2)
Sequencing of NUMB transcripts in chronic myeloid leukemia detects two single nucleotide polymorphisms (2013) (2)
German-austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy (1988) (2)
EBAG 9 Adds a New Layer of Control on Large Dense-Core Vesicle Exocytosis via Interaction with Snapin □ D (2005) (2)
Dendritic cells for autologous tumor vaccination in chronic myeloid leukemia (1997) (2)
H3K9me3-Governed Senescence In Tumor Development and Lymphoma Treatment (2013) (2)
Expression of B-cell-associated antigens during B-cell ontogeny. (1993) (2)
Analysis of Carbohydrate Determinants on Membranes of Leukemic Leukocytes Using Naturally Occurring Monoclonal Human Antibodies (Cold Agglutinins) (1982) (2)
Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation (2013) (1)
Hepatic arterial infusion chemotherapy (HAI) with oxaliplatin (O), 5-fluorouracil (5FU), and folinic acid (FA) in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC): A phase II study (2008) (1)
Long-Term Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Beyond First Complete Remission – a Single Center Experience (2014) (1)
Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (2008) (1)
Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells (2014) (1)
NIH-de fi ned graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia (2013) (1)
Modulation of regulatory T cells and myeloid-derived suppressor cells by sorafenib and sunitinib in renal cell carcinoma patients. (2016) (1)
Purine degradative enzymes in the malignant cells of patients with B-cell leukemia (1985) (1)
Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML (2014) (1)
Abstract 240: Functional impact of p53 hotspot mutantions on tumor development and therapy responses in the Eµ-myc mouse lymphoma model (2011) (1)
T-lymphocyte subpopulations in rheumatoid arthritis. (1980) (1)
Hepatic Arterial Infusion Chemotherapy for Liver Metastases from Gastric Cancer: An Analysis in Western Patients (2011) (1)
Prognostic Impact of a Monosomal Karyotype on the Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation (2011) (1)
Acquired Stem Cell Properties In Therapy-Induced Senescence Of Lymphomas and Acute Leukemias In Vitro and In Vivo (2013) (1)
DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation (2016) (1)
Contrary Functions of NF-κB Signaling in Anti-Cancer Treatment Outcome (2011) (1)
Cisplatin /5-FU (DDP/FU) as 2nd-line chemotherapy after CPT-11 (Irinotecan) failure for patients with metastatic gastric adenocarcinoma (1999) (1)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (2003) (1)
promoting myelopoiesis shift in lineage commitment by suppressing erythropoiesis and Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a (2013) (1)
Elevated post-stimulatory intracellular adenosine 3,5-cyclic monophosphate (cAMP) levels are found in peripheral blood cells after ABMT. (1993) (1)
Simultaneous Cytokine Analysis by Cytometric Bead Array (CBA) Allows More Sensitive Detection of Leukemia-Reactive T Cells in Patients with Chronic Myeloid Leukemia. (2005) (1)
In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine (2007) (1)
TNF alpha therapy activates human B-lymphoma cells in vivo and may protect myelopoiesis. (1992) (1)
Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation (2013) (1)
Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells (2004) (1)
Combined immunochemotherapy (R-FCM) is superior to chemo-therapy (FCM) alone in recurrent indolent lymphoma - results of a prospective randomized comparison (2001) (1)
Analysis of the p53/BAX pathway: Low BAX expression is a negative prognostic factor in patients with resected liver metastases of colorectal adenocarcinoma (1999) (1)
A further subspecificity within human monoclonal anti-Pr cold agglutinins (1982) (1)
Age Predilection of Distinct Phenotypically Defined Subgroups of Non-T Cell ALL: Studies Using B Cell-Restricted or -Associated Monoclonal Antibodies in 359 Patients (1986) (1)
patients with acute myelogenous leukemia Disease-free survival after autologous bone marrow transplantation in (2011) (1)
Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome (2018) (1)
Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1. (2004) (1)
Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis (2016) (1)
Reduced Intensity Versus Standard Myeloablative Conditioning in Patients With Acute Myeloid Leukemia in Second Complete Remission (2011) (0)
Cellular Senescence Contributes to the Outcome of Lymphoma Chemotherapy by Cell-Autonomous and Paracrine Immune Mechanisms (2008) (0)
Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics. (2010) (0)
Costimulatory signals through interaction of B7.1 and CD28 prevent “veto” death of cytotoxic T cells during tumor target cell lysis (1997) (0)
Role of Senescence in Dynamic Tumor/Host Responses to Cancer Therapy In Vivo. (2009) (0)
Long-Term Remission After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Active Disease (2013) (0)
translational control in mammals a genetic model for uORF-mediated − − miceuORF ∆ β C / EBP Material Supplemental (2009) (0)
Combined Positive/Negative Selection in Stem Cell Transplantation: Perspectives in Graft Engineering (1999) (0)
[Flow-cytometric immunophenotyping in clinical diagnostics]. (2016) (0)
Poley S, et al: Serum β2-microglobulin for staging and monitoring of multiple myelomas and other non-Hodgkin lymphomas. Onkologie 1994;17:428-432. (1994) (0)
Session 12 : lymphoma and apoptosis (2011) (0)
Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy. (2006) (0)
The role of p53 hot-spot mutations in MYC-driven lymphoma development and treatement responses in vivo (2006) (0)
Withdrawal: p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. (2023) (0)
Mucin gene (MUC1) transfected dendritic cells as tumor vaccine in patients with breast or pancreatic cancer (1997) (0)
Is gemcitabine (G) reuse possible in early recurrences after its adjuvant application in pancreatic adenocarcinoma (PA) treatment (2015) (0)
myeloablative therapy in a patient with Burkitt's lymphoma Autologous transplantation of blood-derived hemopoietic stem cells after (2011) (0)
Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics. (2010) (0)
Human BDCA-1 Positive Blood Dendritic Cells in Immunosuppressed Patients: Phenotype, Function and Maturation. (2005) (0)
[Possibilities of differential diagnosis by specificity determination of cold agglutinins]. (1977) (0)
Prognostic significance of adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies (1986) (0)
[Monoclonal antibodies in tumor diagnosis and tumor therapy]. (1986) (0)
Arsenic Trioxide Induces Regulated, Death Receptor- and Caspase-Independent Cell Death through the Mitochondrial Death Pathway. (2005) (0)
Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation (2014) (0)
Impact of recurrent cytogenetic abnormalities in INK4a/ARF defective primary lymphomas on chemosensitivity in vivo (2003) (0)
myeloma (MM) cells and signaling cascades mediating survival and proliferation in multiple ) triggers migration α Macrophage inflammatory protein 1-alpha (MIP-1 (2013) (0)
A phase II study in patients with advanced biliary tract carcinoma (BTC) treated with hepatic arterial infusion chemotherapy (HAI) with oxaliplatin (O), 5-fluorouracil (5FU), and folinic acid (FA). (2010) (0)
Sensitivity of B-CLL to Cell Death Induction by Anticancer Drugs Is Independent of the Immunoglobulin Heavy Chain Variable Genes (IgHv) Mutation Status. (2004) (0)
Involvement of BCL-2 and Bax in the IL-7-lnduced Inhibition of Spontaneous Apoptosis in Childhood T-ALL (2001) (0)
[Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy]. (1987) (0)
Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation. (2005) (0)
Complete Contents Vol. 25, 2002 (2002) (0)
Potent Chemoattractant for T Cells and Eosinophils Hodgkin/Reed-Sternberg Cells Induce Fibroblasts to Secrete Eotaxin, a (2013) (0)
Nabpaclitaxel plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubenemia secondary to bile duct obstruction. (2016) (0)
Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission. (2007) (0)
Therapy-Inducible Senescence Activates Both Innate and Adaptive Immune Mechanisms That Control Lymphoma Growth In Vivo (2011) (0)
Protein kinase C inhibitor Sotrastaurin selectively inhibits the growth of CD 79-mutant diffuse large B-cell lymphomas Running title : Sotrastaurin inhibits CD 79 mutant DLBCL (2011) (0)
[Polypoid gastric involvement in plasmacytoma]. (2001) (0)
Loss of Therapy-Induced Senescence in Myc-Driven Lymphomas Compromises Treatment Outcome In Vivo. (2009) (0)
Tumor Necrosis Factor Receptor Expression on Human Normal and Malignant B Lymphocytes: Anti-75-kDa Tumor Necrosis Factor Receptor Antibody Inhibits B-Cell Proliferation (1992) (0)
In-vitro induction of some features of hairy cell leukemia in chronic lymphocytic leukemia and immunocytoma cells (2004) (0)
Corrections to "SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study". (2017) (0)
[Plasmacytomas without paraproteins]. (1985) (0)
Prolonged Stimulation-Induced Pro-Apoptotic B Cells and Deficits in the Germinal Center Formation of Memory B Cells within One Year after Allogeneic HSCT (2015) (0)
MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines (2014) (0)
Vaccines using Gene-Modified Tumor Cells (1999) (0)
Allogeneic Stem Cell Transplantation (SCT) After First Relapse In Adult Patients With Acute Lymphocytic Leukemia (ALL) (2009) (0)
Bcr-Abl and Wilms Tumor Gene (WT1) Kinetics in Nilotinib (AMN107) Treated CML Patients. (2006) (0)
Genetically-engineered allogeneic renal cell carcinoma vaccines (1997) (0)
Perioperative chemotherapy with epirubicin, cisplatin, and 5-FU (ECF) for gastroesophageal cancer: A retrospective analysis. (2010) (0)
B activity in Hodgkin and anaplastic large cell lymphomas κ and NF- β down-regulation of truncated CCAAT enhancer binding protein A rapamycin derivative (everolimus) controls proliferation through (2013) (0)
Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission (2014) (0)
Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study (2017) (0)
Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia (1998) (0)
Subject Index Vol. 124, 2010 (2010) (0)
Role of Bax and Bak in Nbk induced apoptosis (2005) (0)
Targeting Notch and Hedgehog Embryonic Signaling Pathways Has Potent Anti-Tumor Activity in Myeloma and Is Effective in Myeloma Bone Disease. (2012) (0)
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study (2023) (0)
CD95-Mediated Apoptosis in Acute Myeloid Leukemia (AML): Dependence on Maturational Stage and Growth Characteristics in Vitro (1998) (0)
Apoptotic Lymphoma Cells Evoke a Pro-Senescent Stromal Signal That Limits Lymphoma Development. (2009) (0)
Preview : Published ahead of advance online publication EGR 2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia (2016) (0)
Leukocyte alkaline phosphatase in malignancies (1979) (0)
MSI2 and HOXA9 Expression Is Significantly Increased in Patients with Primary Myelofibrosis (2014) (0)
Band 25, Heft 6, December 2002 (2002) (0)
Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation (2015) (0)
Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib (2011) (0)
Comprehensive Risk Factor Analysis in 939 Adults with Acute Myeloid Leukemia Receiving Risk Stratified Post-Remission Therapy: Results of the Prospective Randomized AML96 Trial of the German Study Initiative Leukemia (DSIL). (2007) (0)
Effects of NVP-BSK805, a Novel JAK2 Inhibitor, on BCR-ABL and JAK2V617F Positive Cell Lines (2011) (0)
Pre-Transplant Risk Assessment in Adult Acute Lymphocytic Leukemia (2009) (0)
ROLE OF APOPTOSIS AND CELL CYCLE CONTROL FOR RESPONSE AND SURVIVAL OF COLORECTAL CANCER PATIENTS TREATED WITH PREOPERATIVE RADIOCHEMOTHERAPY ± HYPERTHERMIA (2006) (0)
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial (2014) (0)
Low-dose human recombinant interferon-α-2c ARG (Hu-rIFN-α) in hairy cell-leukemia (HCL): design, recruitment and first observations in a prospective randomized multicenter trial (1986) (0)
Evaluation of predictive factors for thromboembolic events in patients with advanced pancreatic cancer: Evaluation of the CONKO-004 (PROSPECT) study cohort. (2012) (0)
Presence of Bcr-Abl Positive Cells in Peripheral Blood Leukocytes of Immunosuppressed Solid Organ Transplant (SOT) Recipients (2008) (0)
Frequency of a Highly Polymorphic Variant, S36N GFI1, Is Increased in CML Patients (2014) (0)
DNMT3A Mutations In AML: Incidence, Prognostic Influence and Association With Other Molecular Markers (2013) (0)
Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia (2015) (0)
Title Page / Table of Contents (2009) (0)
ATM attenuates Myc-driven lymphomagenesis by sensing oncogene-induced DNA damage in vivo (2005) (0)
Elevated ROS Levels in Response to CD20-Targeting Enhance Senescence Entry after Immunochemotherapy in Human B-Cell Lymphoma (2014) (0)
4. Genetik-Workshop des Robert Koch-Instituts 2/99 in Berlin (1999) (0)
ΝFΚΒΙΕ Deletions : A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma (2016) (0)
Subject Index Vol. 25, 2002 (2002) (0)
Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1 (2015) (0)
Modeling the CNS Tropism of Diffuse Large B-Cell Lymphomas in Vivo (2015) (0)
Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis. (1998) (0)
Role of the pro-apoptotic Bcl-2 homologs Bax and Bak during apoptosis induction by p14ARF (2005) (0)
Internal gallbladder drainage in a patient with malignant cystic duct stenosis due to sarcoma. (2000) (0)
DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties (2016) (0)
A Novel Notch Pathway Inhibitor Blocks Osteoclast Activity and Synergistically Induces Apoptosis with the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cells. (2007) (0)
Hodgkin/Reed-Sternberg cells network, including CD40, CD86, and a set of antiapoptotic genes in B maintains high expression of a characteristic gene κ Constitutive NF- (2014) (0)
A Novel Bioluminescent Mouse Model for Optimization of Adoptive T Cell Therapy (2016) (0)
Chemotherapy for heavily pretreated patients (pts.) with bone (BS) and soft tissue (STS) sarcomas (1997) (0)
Impaired Histone H3 Lysine 9 Methylation Accelerates Ras-Driven Lymphomagenesis by Disabling Cellular Senescence. (2004) (0)
RESTORE & TARGET: a CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN'S LYMPHOMA (2017) (0)
Cd19xcd3 specific polypeptides and their use (1999) (0)
Inactivation of the Myc−Induced DNA Damage Response Promotes Lymphomagenesis and Treatment Resistance In Vivo. (2006) (0)
CD3-Negative CD4+ T-Cells: A Useful Diagnostic Tool with High Specificity in Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma (2008) (0)
Manipulation of the Notch Pathway by γ-Secretase Inhibitors as a Novel Therapeutic Approach in Multiple Myeloma. (2004) (0)
Cross-Species Investigations Reveal Role, Mechanism and Predictive Power of Paracrine, Secondary Senescence in B-Cell Lymphoma Therapy (2012) (0)
Activation-induced cell death of T cells is prevented by coculture with dendritic cells (1997) (0)
[Alpha interferon in the therapy of hairy cell leukemia. Results of 3 prospective multicenter studies in West Germany]. (1988) (0)
Gene expression profiling in renal cell cancer (RCC) during tumor vaccination with a gene-modified allogeneic cancer vaccine: Tumor-induced immunosuppression and a key role for NF-κB. (2014) (0)
Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas B p50 complex formation and Bcl-3 expression in classical κ (2013) (0)
Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients (2016) (0)
Impact of Donor Age on Outcome of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation in Complete Remission (2016) (0)
Liposome-mediated gene transfer into human dendritic cells (1997) (0)
Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC). (2015) (0)
Inactivation of the Suv39h1 Histone Methyltransferase Accelerates Myc-Driven B-Cell Lymphomagenesis and Compromises Drug-Inducible Cellular Senescence. (2005) (0)
Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC). (2008) (0)
[Biochemical markers in lymphatic neoplasms]. (2008) (0)
Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients (2012) (0)
Effect of cytotoxic drugs on the function of the hypothalamo-pituitary-adrenal axis. (1983) (0)
NIH-Defined Graft-Versus-Host Disease in Patients with Acute Lymphoblastic Leukemia: Natural History, Prognostic Impact and Effect of Donor Lymphocyte Infusions (2011) (0)
Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission (2012) (0)
lymphoblastic leukemia interleukin 7, and early cytoreduction in vivo in childhood T-cell acute apoptotic cell death in context of maturation stage, responsiveness to In vitro susceptibility to dexamethasone- and doxorubicin-induced (2013) (0)
Hematopoietic Cell Lines and Patient Samples Show a Correlation Between Upregulated MSI2 and BCR-ABL Expression (2013) (0)
HLA-A0201-positive, IL-7/B7.1-cotransfected allogeneic tumor cells as a vaccine in metastatic renal cell cancer—A clinical phase-I trial (2007) (0)
Expression and Characterization of Leucocyte Antigens (1984) (0)
Prognostic Impact of Different High Risk Features in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission. (2009) (0)
[Basics of molecular diagnostics and therapy of malignant tumors]. (2005) (0)
Lymphotoxin-alpha/beta heterodimer is expressed on leukemic hairy cells and activated human B lymphocytes. (1994) (0)
Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants. (2009) (0)
Contents of Next Issues · Themenvorschau (2002) (0)
Tumor antigen presentation is enhanced by gene modified (IL-7, IL-4 and B7.1) tumor cell vaccines (1997) (0)
Title Pages / Table of Contents (2010) (0)
LYMPHOID NEOPLASIA Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma (2016) (0)
A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCES RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED PRIMARY HUMAN T CELLS (2000) (0)
Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies (2016) (0)
Frequent induction of chromosomal aberrations in in vivo skin fibroblasts after allogeneic stem cell transplantation: hints to chromosomal instability after irradiation (2015) (0)
Complete Contents Vol. 2, 2001 (2001) (0)
Mitoxantrone alone and in combination with cytosine arabinoside in refractory Hodgkin's and non- Hodgkin-lymphoma (1986) (0)
In vitro effects of the novel JAK II inhibitor BSK805 in BCR-ABL and JAK II V617F-positive cell lines. (2011) (0)
of ABC DLBCL B target gene network and survival κ controls the constitutive NF- ζ B- κ I (2013) (0)
Contents Vol. 124, 2010 (2010) (0)
Xenotransplantation of a Novel Hodgkin Cell Line HD-MyZ into SCID Mice (1996) (0)
p38 MAPK Mediates Inhibition of Activation Induced Cell Death in T Lymphocytes Via Upregulation of Bcl-xL and FLIPshort upon Ligation of CD137/4-1BB or CD28. (2005) (0)
[Classification of malignant non-Hodgkin-lymphoma]. (1979) (0)
Anti Leukemic T Cells in Myeloid Neoplasia: Abnormal Cytokine Secretion Patterns May Prevent Immunological Detection and Possibly Reflect Functional Impairment. (2006) (0)
Brain metastases (BM) in breast cancer (BC): Prognostic factors and management in 162 patients (1997) (0)
Arsenic Trioxide-Induced Cell Death Occurs Partially Independent of the Pro-Apoptotic Bcl-2-Family Members Bax and Bak. (2006) (0)
Combined Risk-Factor Analysis Predicts Outcome of AML Patients After Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (2009) (0)
No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia. (2006) (0)
disease transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin Loss of PU.1 expression is associated with defective immunoglobulin (2013) (0)
Complement-mediated cytolysis: quantification of B cell surface antigen molecules and role of cell cycle. (1988) (0)
1 CD 20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma (2017) (0)
Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC). (2008) (0)
Abstract 3538: An atomic absorption spectroscopy assay (AASA) as a surrogate method to measure imatinib (IM) uptake via the organic cation transporter 1 (OCT1) (2010) (0)
CONKO-101: Results of a multicenter phase II study of an outpatient regimen consisting out of gemcitabine, 5-FU (24h CI), folinic acid and cisplatin for patients with inoperable esophageal cancer. (2006) (0)
Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib. (2010) (0)
Activating Transcription Factor 3 (ATF3) Is Overexpressed in Classical Hodgkin Lymphoma and Is Required for Survival of Hodgkin and Reed-Sternberg Cells in Response to Cellular Stress. (2004) (0)
Costimulation with agonistic anti-CD28 antibodies prevents T cell apoptosis and is required for efficient immunotherapy with CD3x19 bispecific antibodies in B cell lymphoma (1997) (0)
cross-species investigations B in anti-cancer treatment outcome unveiled by κ Opposing roles of NF-Material Supplemental (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bernd Dörken?

Bernd Dörken is affiliated with the following schools:

Bernd Dörken's Academic­Influence.com Rankings

Bernd Dörken's Degrees

Why Is Bernd Dörken Influential?

Bernd Dörken's Published Works

Published Works

What Schools Are Affiliated With Bernd Dörken?

Bernd Dörken's AcademicInfluence.com Rankings